Patients drop MS drug, face relapse risk
A study of discontinuing natalizumab for multiple sclerosis patients testing positive for JC virus antibody found a higher relapse rate within 6 months than for patients continuing the… read more.
A study of discontinuing natalizumab for multiple sclerosis patients testing positive for JC virus antibody found a higher relapse rate within 6 months than for patients continuing the… read more.
by Maria Dalby reporting on the presentation by Miriam Manook et al, Guy’s Hospital, London. Adequate training of transplant surgeons is essential for good clinical outcomes. Although surgical… read more.
A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in… read more.
by Bruce Sylvester – Stroke patients with a history of stroke or diabetes who received clot-busting drugs post-stroke have achieved better outcomes than those who did not receive… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.